Latest Health Insurance News

FINEOS Corporation reports robust FY25 financial performance, driven by subscription revenue growth and embedded AI innovations, setting a confident outlook through FY27.

Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Ramsay Health Care’s half-year results reveal a dramatic net profit rebound, driven by prior year impairments and solid growth in Australia and Europe. The company also announced a strategic acquisition and a proposed share distribution.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

nib holdings limited reported a stable net profit of $82.9 million for the half year ended 31 December 2025, supported by 6% revenue growth and disciplined expense management. The Board declared a fully franked interim dividend of 13.0 cents per share.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

nib Group has announced a 5.47% average increase in health insurance premiums for 2026, citing rising hospital costs and increased claims. The insurer highlights efforts to ease out-of-pocket expenses and support chronic illness management amid sector-wide pressures.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.